Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT02536118

Micra Transcatheter Pacing System Post-Approval Registry

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
3,100 (actual)
Sponsor
Medtronic · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Medtronic is sponsoring the Micra Registry to further confirm safety and effectiveness of the Micra Transcatheter Pacing System (Micra system) when used as intended, in "real-world" clinical practice, following commercial release. The Micra Registry is conducted within Medtronic's Product Surveillance Registry.

Detailed description

The Micra Registry is a global, prospective, observational, multi-site registry. Patients enrolled in the Micra Registry will be prospectively followed for a minimum of 9 years post-implant or until registry closure, patient death, patient exit from the registry (i.e., withdrawal of consent), or unless patient is participating in an acute performance sub-study of the Micra Registry\*. Enrolled patients will have scheduled follow-up visits at least annually or as prompted by reportable adverse events; however, all Micra system follow-up patient visits are to be reported. Therefore, if more frequent scheduled visits occur per a provider's standard care practice, those visits are reported. The total estimated registry duration is 11 years. \*Patients contributing to an acute performance sub-study of the Micra Registry do not contribute to the FDA-regulated Post-Approval Study which includes a long-term (minimum 9-year) patient follow-up period.

Conditions

Interventions

TypeNameDescription
DEVICEMicra Transcatheter Pacing SystemThe Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.

Timeline

Start date
2015-07-01
Primary completion
2027-04-01
Completion
2027-04-01
First posted
2015-08-31
Last updated
2026-02-04

Locations

156 sites across 24 countries: United States, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Iceland, Israel, Italy, Japan, Kuwait, Netherlands, New Zealand, Norway, Poland, Portugal, Saudi Arabia, Spain, Sweden, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT02536118. Inclusion in this directory is not an endorsement.